CCCC on Nasdaq
C4 Therapeutics (United States)
Company in Watertown, United States.1
Price unavailable
Last updated Oct 16, 2026.
Overview
2015Founded1
Compare with X4 Pharmaceuticals, Inc, Precision BioSciences or Scholar Rock Holding Corp, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-320.5%Operating margin4
-292.1%Net margin4
1.0%Revenue growth, 20254
-40.9%Return on equity4
-$99.3MFree cash flow4
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development100¢$104.2M
- Income tax0¢$121.0K
Out of $35.9M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue from collaboration agreements | $35.9M | $35.6M |
| Research and development | $104.2M | $110.6M |
| General and administrative | $36.2M | $42.1M |
| Impairment loss on right-of-use asset | $10.7M | $0 |
| Restructuring | $0 | $2.4M |
| Total operating expenses | $151.2M | $155.2M |
| Loss from operations | -$115.2M | -$119.6M |
| Interest and other income, net | $10.3M | $14.4M |
| Total other income, net | $10.3M | $14.4M |
| Loss before income taxes | -$104.9M | -$105.2M |
| Income tax expense | -$121.0K | -$131.0K |
| Net loss | -$105.0M | -$105.3M |
| Net loss per share basic (in dollars per share) | -$1.27 | -$1.52 |
| Net loss per share diluted (in dollars per share) | -$1.27 | -$1.52 |
| Weighted-average number of shares - basic (in shares) | 82.9M shares | 69.4M shares |
| Weighted-average number of shares - diluted (in shares) | 82.9M shares | 69.4M shares |
| Unrealized (loss) gain on marketable securities | -$3.0K | $180.0K |
| Comprehensive loss | -$105.0M | -$105.1M |
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2025-06-30 | 2024-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $74.6M | $55.5M | |
| Marketable securities, current | $173.9M | $189.4M | |
| Accounts receivable | $2.4M | $3.1M | |
| Prepaid expenses and other current assets | $7.2M | $9.8M | |
| Total current assets | $258.1M | $257.8M | |
| Marketable securities, non-current | $48.6M | $22.4M | |
| Property and equipment, net | $4.7M | $5.8M | |
| Right-of-use asset | $40.5M | $57.5M | |
| Restricted cash | $3.4M | $3.4M | |
| Other assets | $3.7M | $2.7M | |
| Total assets | $359.1M | $349.6M | |
| Accounts payable | $858.0K | $1.3M | |
| Accrued expenses and other current liabilities | $13.3M | $19.4M | |
| Deferred revenue, current | $12.5M | $18.7M | |
| Operating lease liability, current | $6.4M | $5.8M | |
| Total current liabilities | $33.0M | $45.2M | |
| Deferred revenue, net of current | $15.8M | $28.5M | |
| Operating lease liability, net of current | $53.6M | $60.0M | |
| Total liabilities | $102.5M | $133.6M | |
| Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized, and no shares issued or outstanding as of December 31, 2025 and 2024, respectively | $0 | $0 | |
| Common stock, par value of $0.0001 per share; 300,000,000 and 150,000,000 shares authorized as of December 31, 2025 and December 31, 2024, and 96,914,418 and 70,625,899 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $9.0K | $7.0K | |
| Additional paid-in capital | $995.2M | $849.6M | |
| Accumulated other comprehensive income | $50.0K | $53.0K | |
| Accumulated deficit | -$738.7M | -$633.7M | |
| Total stockholders equity | $256.6M | $216.0M | |
| Total liabilities and stockholders equity | $359.1M | $349.6M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 300.0M shares | 300.0M shares | 150.0M shares |
| Common stock, shares issued | 96.9M shares | 70.6M shares | |
| Common stock, shares outstanding | 96.9M shares | 70.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$105.0M | -$105.3M |
| Stock-based compensation expense | $19.1M | $29.7M |
| Impairment loss on right-of-use asset | $10.7M | $0 |
| Depreciation and amortization | $2.0M | $1.8M |
| Reduction in carrying amount of right-of-use asset | $6.4M | $6.4M |
| Accretion of premium on marketable securities | -$2.7M | -$5.4M |
| Other | $99.0K | $6.0K |
| Accounts receivable | $701.0K | $8.7M |
| Prepaid expenses and other current and long-term assets | $1.1M | -$4.3M |
| Accounts payable | -$468.0K | -$119.0K |
| Accrued expenses and other current liabilities | -$6.0M | -$1.3M |
| Operating lease liability | -$5.8M | -$5.2M |
| Deferred revenue | -$18.8M | $9.9M |
| Net cash used in operating activities | -$98.7M | -$65.2M |
| Proceeds from maturities of marketable securities | $219.1M | $233.2M |
| Purchase of marketable securities | -$227.1M | -$284.3M |
| Purchases of property and equipment | -$607.0K | -$180.0K |
| Net cash used in investing activities | -$8.6M | -$51.3M |
| Proceeds from exercises of stock options | $107.0K | $778.0K |
| Payments for repurchase of common stock for tax withholding | -$193.0K | -$194.0K |
| Other | $274.0K | $382.0K |
| Net cash provided by financing activities | $126.4M | $45.3M |
| Net change in cash, cash equivalents and restricted cash | $19.1M | -$71.1M |
| Stock issuance costs | $8.1M |
Compare C4 Therapeutics (United States) with another company
Timeline
- 2015Founded Founded1
Recent filings
- Oct 2, 20264
- Oct 2, 20264
- Sep 25, 20268-K
- Sep 21, 20264
- Aug 14, 2026SCHEDULE 13G/A
- Aug 14, 2026SCHEDULE 13G/A
- Aug 14, 2026SCHEDULE 13G/A
- Aug 14, 2026144
- Aug 14, 2026144
- Aug 13, 2026144
- Aug 12, 2026SCHEDULE 13G/A
- Aug 12, 2026144
- Aug 11, 20268-K
- Aug 11, 202610-Q
- Jul 27, 2026SCHEDULE 13G
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitec4therapeutics.com1
- WikidataQ64142088
- SEC EDGARCIK 1662579
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11